InvestSMART

Biotron Limited (ASX: BIT) - Announcements

Current share price for BIT : $0.003 0.001 (16.67%)+

ASX company news and announcements for Biotron Limited (BIT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Biotron Limited (BIT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Biotron Limited (BIT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Biotron Limited (BIT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Share Purchase Plan and $2.5 Million Underwriting Agreement 16 Nov 2007 6:01PM $0.170 $0.003 fallen by 98.53%
$7 Response to ASX Quarterly Appendix 4C Query 7 Nov 2007 9:47AM $0.190 $0.003 fallen by 98.68%
$7 Commercial Ready Grant Received 6 Nov 2007 11:35AM $0.190 $0.003 fallen by 98.68%
$7 Appendix 4C - quarterly 30 Oct 2007 4:25PM $0.205 $0.003 fallen by 98.78%
$7 Year End Accounts and Preliminary Final Report Appendix 4E 28 Aug 2007 3:25PM $0.230 $0.003 fallen by 98.91%
$7 BIT225 Phase I Clinical Trial Successfully Completed 16 Aug 2007 12:18PM $0.210 $0.003 fallen by 98.81%
$7 Response to ASX Query 7 Aug 2007 5:48PM $0.240 $0.003 fallen by 98.96%
$7 BIT225 Highly Synergistic with Current Anti-HCV Therapies 7 Aug 2007 10:24AM $0.240 $0.003 fallen by 98.96%
$7 Hepatitis B Antiviral Program and Phase I Trial Update 10 Jul 2007 11:21AM $0.270 $0.003 fallen by 99.07%
$7 Commitments Test Entity - Third Quarter Report 20 Apr 2007 4:38PM $0.285 $0.003 fallen by 99.12%
$7 Begins Phase I Clinical Trial of its HIV Drug BIT225 22 Mar 2007 10:32AM $0.295 $0.003 fallen by 99.15%
$7 Half Yearly Report & Half Year Accounts 26 Feb 2007 12:29PM $0.285 $0.003 fallen by 99.12%
$7 Hepatitis C Virus Program Advanced 9 Feb 2007 10:24AM $0.300 $0.003 fallen by 99.17%
$7 Commitments Test Entity - Second Quarter Report 23 Jan 2007 12:48PM $0.275 $0.003 fallen by 99.09%
$7 Successful Completion of Preclinical Program for HIV Drug 23 Jan 2007 10:28AM $0.275 $0.003 fallen by 99.09%
$7 Agreement with ANU - Enhancement of Antiviral Program 22 Dec 2006 11:45AM $0.230 $0.003 fallen by 98.91%
$7 Commitments Test Entity - First Quarter Report 19 Oct 2006 11:10AM $0.265 $0.003 fallen by 99.06%
$7 Biotron Compounds Show HCV Activity 20 Sep 2006 12:20PM $0.215 $0.003 fallen by 98.84%
$7 Preliminary Final Report/Annual Report 13 Sep 2006 9:07AM $0.210 $0.003 fallen by 98.81%
$7 Commitments Test Entity - Fourth Quarter Report 18 Jul 2006 10:04AM $0.250 $0.003 fallen by 99%
$7 Commitments Test Entity - Third Quarter Report 20 Apr 2006 10:13AM $0.250 $0.003 fallen by 99%
$7 Prospectus & Letter to Shareholders 22 Mar 2006 5:27PM $0.260 $0.003 fallen by 99.04%
$7 New Issue Announcement 15 Mar 2006 12:26PM $0.235 $0.003 fallen by 98.94%
$7 Half Yearly Report to 31 December 2005 2 Mar 2006 4:46PM $0.264 $0.003 fallen by 99.05%
$7 Compounds Active against Bird Flu 24 Feb 2006 11:29AM $0.365 $0.003 fallen by 99.31%

551 - 575 of 594 results

Page 23 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.